NDA 019407 · Kenvue Brands
Visine L.R.
Oxymetazoline Hydrochloride · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Nov 1, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Mar 31, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
655
76 Phase 3, 27 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 31, 1989 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- VISINE L.R. · OXYMETAZOLINE HYDROCHLORIDE 0.025% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxymetazoline" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac SurgeryPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06802224 · 18,000 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 2028
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery and 4 more
Sites: San Francisco, California; College Park, Maryland; Ann Arbor, Michigan · 10 sites in all
- The GUARDIAN Trial - Vasopressor Sub-StudyPivotal-lookingEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT04934748 · 6,254 participants (planned) · Start Jul 25, 2021 · Primary completion Dec 31, 2026
Drug: Phenylephrine; Norepinephrine · For: Blood Pressure
Sites: Omaha, Nebraska; Cleveland, Ohio; Beijing, China · 11 sites in all
- Norepinephrine vs Phenylephrine During General AnesthesiaPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04789330 · 3,626 participants · Start Jul 1, 2021 · Primary completion Apr 1, 2022
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery; Hypotension
Sites: Los Angeles, California; San Francisco, California · 5 sites in all
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- OB VEGA-Phenylephrine vs Norepinephrine OutcomesPivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07900919 · 1,500 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: Phenylephrine; Norepinephrine · For: Hypotension During Surgery; Cesarean Birth
Sites: Winston-Salem, North Carolina
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac SurgeryPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05635227 · 1,200 participants (planned) · Start Nov 10, 2022 · Primary completion Dec 2027
Drug: Dexamethasone phosphate; Isotonic sodium chloride (0.9%) and 2 more · For: Coronary Artery Disease; Aortic Valve Disease
Sites: Copenhagen, Denmark
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-GrowthPivotal-lookingNot yet recruiting
Applied Biology, Inc.Industry
NCT06648850 · 1,120 participants (planned) · Start May 1, 2026 · Primary completion Mar 19, 2027
Drug: DA-001; Phenylephrine and 1 more · For: Telogen Effluvium; Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia and 3 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I · J Cosmet Dermatol 2022 · Systematic Review
- Common cold.
Arroll B · BMJ Clin Evid 2008 · Systematic Review
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
- Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.
Neighbors CL, Salvador CF, Zhu B, et al. · J Laryngol Otol 2022 · Systematic Review
- The effects of nasal decongestion on obstructive sleep apnoea.
An Y, Li Y, Kang D, et al. · Am J Otolaryngol 2019 · Randomized Controlled Trial
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.